Skip to main
  1. Stocks
  2. PolyPid
  3. Forecast
PYPD

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid is supported by a strong clinical and regulatory setup for D-PLEX100, with SHIELD II showing about a 60% reduction in incisional surgical-site infections and the NDA already under Priority Review for the November 28, 2026 PDUFA. The company’s partnership with Azurity materially de-risks commercialization by funding launch and label-expansion work while still leaving PolyPid with tiered mid-teens to mid-20s royalties, manufacturing revenue, and over $290M of potential milestones after the $30M already received. Fundamentally, the balance sheet also improved, as 3Q26 net loss narrowed to $5.8M and pro forma cash rose to about $30.5M, giving management runway into 2028 while broader abdominal surgery, Europe, and PD01B add longer-term upside.

Bears say

PolyPid is viewed negatively because its valuation is tied almost entirely to D-PLEX100, which is still under FDA review with a November 28, 2026 PDUFA date and remains exposed to a CRL, extra study request, or restrictive label that could narrow the market. Even if approved, commercialization depends on Azurity’s execution, hospital-by-hospital formulary adoption, and uncertain reimbursement, including a possible denial of FY2028 NTAP that could leave hospitals absorbing full product cost and keep penetration in the low single digits through 2028. The company also faces manufacturing and financing risk, as FDA inspection or supply issues could delay launch while slower uptake could force dilutive financing, and bears note a modest upfront deal, limited near-term revenue, and a June 2025 warrant overhang.

PolyPid (PYPD) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

PolyPid (PYPD) Analyst Forecast & Price Prediction

Get the latest PolyPid (PYPD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PolyPid (PYPD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Buy based on their latest research and market trends.

According to 2 analysts, PolyPid (PYPD) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


PolyPid (PYPD) Analyst Forecast & Price Prediction

Get the latest PolyPid (PYPD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PolyPid (PYPD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PYPD stock data and trends